Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...
Minimal residual disease (MRD) is becoming one of the most important response biomarkers in oncology development. Once viewed primarily as a hematologic endpoint, MRD is now influencing broader ...
MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
Former Castle Biosciences SVP brings proven diagnostic commercialization and reimbursement leadership to NovaScan’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results